Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03845660 · ClinicalTrials.gov registry record · NA
Risk EValuation And Its Impact on ClinicAL Decision Making and Outcomes in Heart Failure
A NA study of Heart Failure, sponsored by Yale University.
- Completed
- Registry status
- NA
- Development phase
- 3,124
- Enrollment target
- 1
- Study location
NCT03845660 is a NA study of Heart Failure that has completed, run by Yale University. The registered enrollment target is 3,124 participants, above the 2,041-participant average among 397 other Heart Failure trials with a reported enrollment target (53% higher). The trial reports 1 study location across 1 state.
The verdict
NCT03845660, a NA study of Heart Failure, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- NA
- Development phase
- 3,124 participants
- Enrollment target
- 1
- Study location
Study Summary
Heart failure is a complex and heterogenous disease with mortality and morbidity that equals more cancers. Numerous studies have examined the ability to improve prognostication from heart failure, ranging from basic statistical methodologies to machine learning, with impressive improvements in both predictive indices. However, no study to date has examined, in a randomized fashion, the impact of providing prognostic information on provider behavior and downstream clinical outcomes. It is for this reason that the investigators plan to perform the Risk EValuation And Its Impact on ClinicAL Decision Making and Outcomes in Heart Failure (REVeAL-HF) Trial within the Yale New Haven Health System. REVeAL-HF is a randomized, single-blind intervention trial that is testing the clinical impact of providing prognostic information to the provider on heart failure outcomes in the inpatient settings. The study hypothesis is that electronic alerting about prognostic information on heart failure patients along with links to guidelines will lead to reductions in all-cause mortality and 30-day HF hospitalizations via improved use of guideline directed medical therapy and more adequate decongestion.
Conditions Studied
Interventions
- BEHAVIORAL Electronic Alert
Study Locations (1)
Connecticut
- Yale New Haven Hospital - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,124 participants |
| Start Date | 2020-01-01 |
| Est. Completion | 2021-12-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03845660
The ClinicalTrials.gov registry entry for NCT03845660 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 3,124 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 2,041-participant average among 397 other Heart Failure trials with a reported enrollment target (53% higher). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Heart Failure appearing as the primary indexed condition, and to 1 intervention - of which Electronic Alert is the first listed.
NCT03845660 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT03845660 about?
NCT03845660 is a clinical study titled "Risk EValuation And Its Impact on ClinicAL Decision Making and Outcomes in Heart Failure". Heart failure is a complex and heterogenous disease with mortality and morbidity that equals more cancers. Numerous studies have examined the ability to improve prognostication from heart failure, ranging from basic statistical methodologies to machine learning, with impressive improvements in both ...
What is the current status of trial NCT03845660?
This trial is currently completed. It is a NA study. The enrollment target is 3,124 participants. The study started on 2020-01-01. Estimated completion is 2021-12-30.
What conditions does trial NCT03845660 study?
This clinical trial studies the following conditions: Heart Failure.
What interventions are being tested in trial NCT03845660?
The interventions under investigation include: Electronic Alert (BEHAVIORAL).
Who is sponsoring clinical trial NCT03845660?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03845660 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Early Feasibility Study of the NORM™ System in Heart Failure Patients (FUTURE-HFII)
RECRUITING · NA
-
Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure
RECRUITING · NA
-
iCardia4HF: Multi-component mHealth Intervention for Patients With Heart Failure
RECRUITING · NA
-
Optimizing Heart Failure Therapies Among Patients With Limited Access in Denver
RECRUITING · NA
-
Hemodynamic Monitoring to Prevent Adverse Events foLlowing cardiOgenic Shock Trial
RECRUITING · NA
-
Effect of a Quality Improvement Initiative to Address Social Determinants of Health on Rehospitalization Rates in Patients With Heart Failure
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.